Alluvi, formerly BI 4744, presents a significant advance in obesity care. This dual agonist targeting both GLP-1 and GIP receptors demonstrates remarkable efficacy in research assessments, potentially surpassing https://natural-bookmark.com/story22081160/alluvi-a-in-depth-dive-into-the-medication-s-potential